Cargando…
Efficacy of cell-free DNA methylation-based blood test for colorectal cancer screening in high-risk population: a prospective cohort study
BACKGROUND: Although colonoscopy is the standard screening test for colorectal cancer (CRC), its use is limited by a poor compliance rate, the need for extensive bowel preparation, and the risk of complications. As an alternative, an FDA-approved stool-based DNA test, Cologuard, has demonstrated sat...
Autores principales: | Zhao, Fuqiang, Bai, Ping, Xu, Jianfeng, Li, Zitong, Muhammad, Shan, Li, Diange, Zhang, Zeyue, Gao, Yibo, Liu, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538018/ https://www.ncbi.nlm.nih.gov/pubmed/37770864 http://dx.doi.org/10.1186/s12943-023-01866-z |
Ejemplares similares
-
FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study
por: Zhao, Shengbing, et al.
Publicado: (2022) -
A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma
por: Kim, Si-Cho, et al.
Publicado: (2023) -
Impairment of colorectal cancer screening during the COVID-19 pandemic
por: Laghi, Luigi, et al.
Publicado: (2021) -
Impairment of colorectal cancer screening during the COVID-19 pandemic
por: Semenov, Serhiy, et al.
Publicado: (2021) -
Inaccuracies and shortcomings in “Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations”
por: Johansen Taber, Katherine, et al.
Publicado: (2019)